Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Michel, Bazinet"'
Autor:
Michel Bazinet, Mark Anderson, Victor Pântea, Gheorghe Placinta, Iurie Moscalu, Valentin Cebotarescu, Lilia Cojuhari, Pavlina Jimbei, Liviu Iarovoi, Valentina Smesnoi, Tatina Musteata, Alina Jucov, Ulf Dittmer, Jeff Gersch, Vera Holzmayer, Mary Kuhns, Gavin Cloherty, Andrew Vaillant
Publikováno v:
Hepatology Communications, Vol 6, Iss 8, Pp 1870-1880 (2022)
Abstract Nucleic acid polymers block the assembly of hepatitis B virus (HBV) subviral particles, effectively preventing hepatitis B surface antigen (HBsAg) replenishment in the circulation. Nucleic acid polymer (NAP)–based combination therapy of HB
Externí odkaz:
https://doaj.org/article/1439c3a20ee643779b91b7a1ae39620f
Autor:
Michel Bazinet, Mark Anderson, Victor Pântea, Gheorghe Placinta, Iurie Moscalu, Valentin Cebotarescu, Lilia Cojuhari, Pavlina Jimbei, Liviu Iarovoi, Valentina Smesnoi, Tatina Musteata, Alina Jucov, Ulf Dittmer, Jeff Gersch, Vera Holzmayer, Mary Kuhns, Gavin Cloherty, Andrew Vaillant
Publikováno v:
Hepatology Communications, Vol 5, Iss 11, Pp 1873-1887 (2021)
Therapy with nucleic acid polymers (NAPs), tenofovir disoproxil fumarate (TDF), and pegylated interferon (pegIFN) achieve high rates of HBsAg loss/seroconversion and functional cure in chronic hepatitis B virus (HBV) infection. The role of hepatitis
Externí odkaz:
https://doaj.org/article/4962844ee1414e3d96bfdaa6fe8cc674
Autor:
Michel Bazinet, Victor Pântea, Valentin Cebotarescu, Lilia Cojuhari, Pavlina Jimbei, Mark Anderson, Jeff Gersch, Vera Holzmayer, Carina Elsner, Adalbert Krawczyk, Mary C. Kuhns, Gavin Cloherty, Ulf Dittmer, Andrew Vaillant
Publikováno v:
Hepatology Communications, Vol 5, Iss 2, Pp 189-202 (2021)
The nucleic acid polymer REP 2139 inhibits assembly/secretion of hepatitis B virus (HBV) subviral particles. Previously, REP 2139‐Ca and pegylated interferon (pegIFN) in HBV/hepatitis delta virus (HDV) coinfection achieved high rates of HDV RNA and
Externí odkaz:
https://doaj.org/article/b53db796d87843aebc8a9813dabe6e78
Autor:
Liviu Iarovoi, Adalbert Krawczyk, Alina Jucov, Lilia Cojuhari, Ulf Dittmer, Valentin Cebotarescu, Iurie Moscalu, Victor Pântea, Pavlina Jimbei, Michel Bazinet, Andrew Vaillant, Valentina Smeşnoi, Gheorghe Plăcintă, Tatiana Musteata
Publikováno v:
Journal of Viral Hepatitis. 28:817-825
Treatment of HBV infection with nucleic acid polymers and pegIFN is accompanied by transaminase elevations in 95% of participants. HBV viral rebound, partial cure (HBV DNA 2000 IU/mL, normal ALT) or functional cure (HBV DNA target not detected, HBsAg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc62254769a89e02affbbad2d2bcf1d6
https://doi.org/10.1111/jvh.13483
https://doi.org/10.1111/jvh.13483
Publikováno v:
PLoS ONE, Vol 11, Iss 6, p e0156667 (2016)
UNLABELLED:Previous in vivo studies have suggested that nucleic acid polymers (NAPs) may reduce circulating levels of HBsAg in the blood by blocking its release from infected hepatocytes and that this effect may have clinical benefit. NAP treatment,
Externí odkaz:
https://doaj.org/article/fad2268de379457d9165bab3e73ba0a0
Autor:
Adalbert Krawczyk, Louis M. Shekhtman, Harel Dahari, Valentin Cebotarescu, Pavlina Jimbei, Susan L. Uprichard, Leeor Hershkovich, Michel Bazinet, Ulf Dittmer, Lilia Cojuhari, Scott J. Cotler, Andrew Vaillant, V. Pantea
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-7 (2020)
Scientific Reports
Scientific Reports
Hepatitis D virus (HDV) requires hepatitis B surface antigen (HBsAg) for its assembly and release. Current HBV treatments are only marginally effective against HDV because they fail to inhibit HBsAg production/secretion. However, monotherapy with the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ee3f0194b7b3bb5acd9f54a0daf41f9
http://link.springer.com/article/10.1038/s41598-020-64122-0
http://link.springer.com/article/10.1038/s41598-020-64122-0
Autor:
Leeor Hershkovich, Louis Shekhtman, Michel Bazinet, Mark Anderson, Mary Kuhns, Gavin Cloherty, Scott Cotler, Andrew Vaillant, Harel Dahari
Publikováno v:
Journal of Hepatology. 77:S851-S852
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed40f3de539ff0b7cdd86acb559812d1
https://doi.org/10.1016/s0168-8278(22)02000-1
https://doi.org/10.1016/s0168-8278(22)02000-1
Autor:
Andrew Vaillant, Mamun Al-Mathab, Hadi Karimzadeh, Michel Bazinet, Martin Däumer, Dmitrij Frishman, Hrvoje Mijočević, Zainab Usman, Michael Roggendorf
Publikováno v:
Journal of Viral Hepatitis. 26:1454-1464
Chronic HBV infection results in various clinical manifestations due to different levels of immune response. In recent years, hepatitis B treatment has improved by long-term administration of nucleos(t)ide analogues (NUCs) and peg-interferon. Nucleic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aeffceb2dcaef3ca62e7e52bbe0a4582
https://doi.org/10.1111/jvh.13180
https://doi.org/10.1111/jvh.13180
Autor:
Pavlina Jimbei, Valentin Cebotarescu, Gavin Cloherty, Lilia Cojuhari, Adalbert Krawczyk, Ulf Dittmer, Mark S. Anderson, Carina Elsner, Mary C. Kuhns, Vera Holzmayer, Jeff Gersch, Andrew Vaillant, Victor Pântea, Michel Bazinet
Publikováno v:
Hepatology Communications
Hepatology Communications, Vol 5, Iss 2, Pp 189-202 (2021)
Hepatology Communications, Vol 5, Iss 2, Pp 189-202 (2021)
Finite therapy of HBV/HDV co‐infection with REP 2139‐Ca and pegIFN has good long term safety and is accompanied by high rates of functional cure of HDV, normalization of liver function and additional functional cure of HBV. HBV functional cure is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07d8bdfc8ddfdbd5ca4e34135f0f18aa
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85113940652
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85113940652
Autor:
Michel Bazinet, Mark Anderson, Victor Pantea, Gheorghe Placinta, Iurie Moscalu, Valentin Cebotarescu, Lilia Cojuhari, Pavlina Jimbei, Liviu Iarovoi, Valentina Smesnoi, Tatiana Musteata, Alina Jucov, Jeff Gersch, Vera Holzmayer, Mary Kuhns, Gavin Cloherty, Andrew Vaillant
Publikováno v:
Journal of Hepatology. 73:S142
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::205845ecf65b8a10a1944d53527a7de9
https://doi.org/10.1016/s0168-8278(20)30793-5
https://doi.org/10.1016/s0168-8278(20)30793-5